The United Nations Office at Geneva
Multimedia Newsroom
STORYLINE
Injectable HIV medicines deal to provide access to generic lifesaver in developing nations
A landmark agreement has been reached allowing for the production of low-cost, injectable HIV medicines in some 90 developing countries where more the majority of infections occur, UNITAID said on Friday.
Selected manufacturers will be able to develop, manufacture and supply lower-cost generic versions of long-acting Cabotegravir (CAB-LA), in line with a deal reached with pharmaceutical firm ViiV Healthcare (ViiV).
“The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to Cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries,” said UNITAID spokesperson Hervé Verhoosel.
The deal is significant because Cabotegravir injections are only needed once every few months. Increasing its supply at a cost that is affordable to low-income countries could help to overcome the stigma that’s associated with taking daily HIV pills - and the burden of having to remember to take them.
“In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV won’t ask for any royalty on the product and for 10 of those countries, ViiV is asking for a smaller-than-usual royalty,” Mr. Verhoosel explained.
The agreement comes after UNITAID-led discussions began in May this year with ViiV, a subsidiary of pharma giant GlaxoSmithkline. It is only seven months since Cabotegravir LA received regulatory approval.
But the process of selecting the companies that will develop, manufacture and supply generic versions of Cabotegravir will take much longer.
“This product will not be there for everybody, that’s first for people who are there the most at risk,” said Mr. Verhoosel, who noted that the cost of the medicine in the US when it comes onstream there “really soon”, was likely to be around $20,000. “That’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
According to UNITAID, the deal offers the possibility of making the injectable prophylactic medicine available in 90 countries where more than 70 per cent of all new HIV infections occurred in 2020.
Up to three drug manufacturers will be licensed to develop the product on a generic basis to avoid supply and distribution issues. “That’s done in a way that we’re sure (that) one, it’s easy for logistics, two…availability, and three, of course, that it will help to bring the cost of the generic version down”, said Mr. Verhoosel.
ends
STORY: Injectable HIV Prevention Medicines Deal - UNITAID
TRT: 02’05”
SOURCE: UNTV CH
RESTRICTIONS: NONE
LANGUAGE: ENGLISH/NATS
ASPECT RATIO: 16:9
DATELINE: Friday 29 July 2022, GENEVA, SWITZERLAND
SHOTLIST
- Medium shot, UN Geneva flag alley.
- Wide shot, press room with panel of speakers, journalists, TV camera on tripod.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries.”
- Medium shot, lateral, podium speakers.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV (ViiV Healthcare) don’t ask any royalty on the product and for 10 of those countries ViiV is asking for a smaller-than-usual royalty.”
- Wide shot, journalists, TV camera, light panel.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “This product will not be there for everybody, that’s first for people who are there the most at risk. That’s a product that’s available in the US, and the price of that product for one year in the US for example is approximately 20,000 US dollars, and that’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
- Medium shot, journalists seated at tables, TV camera.
- SOUNDBITE (ENGLISH) Hervé Verhoosel, UNITAID: “This licence will actually give the option to three different generic manufacturers to develop the product on a generic base. That means that the price that those companies will have we don’t know yet, but that will not only be one company, that will be three different companies and that’s done in a way that we’re sure one, that it’s easy for logistics, two, that ensuring availability, and three, of course, that it will help to bring the cost of the generic version down.”
- Medium shot, journalists.
- Wide shot, journalists, TV camera and light panel.
- Medium shot, journalist.
- Medium shot, journalists, side shot.
Similar Stories
1
1
1
Edited News | OHCHR
A UN Human Rights Office report released today covers 19 months of large-scale violations of international law including atrocity crimes, from October 2023 to the end of May 2025.
1
1
1
Edited News | OCHA , UNICEF
At least six million people in Somalia are going days without enough food, UN aid teams warned on Friday, highlighting that nearly two million of this number are young children “at high risk of illness or death”.
1
1
1
Edited News | UNICEF , WHO
Children shot, stabbed and pepper-sprayed in occupied West Bank; scores of Gaza amputees denied prosthetics, aid teams warn
Israeli military operations and surging settler attacks in the occupied West Bank are killing and maiming Palestinian children, while in Gaza tens of thousands with life-changing injuries lack access to treatment and rehabilitation, UN agencies warned on Tuesday.
1
1
1
Edited News | WHO
The risk of hantavirus spreading to the general population is “absolutely low”, the UN World Health Organization (WHO) stressed on Friday.
1
1
1
Edited News | UNHCR , IFRC
Death and destruction have continued unabated in Lebanon while communities are still unable to return to their homes despite a ceasefire that began on 17 April, humanitarians said on Tuesday.
1
1
Edited News | WHO
Deadly hantavirus on board cruise ship may be transmitted among humans - WHO
Hantavirus victims on a ship in the Atlantic Ocean may have been infected prior to joining the cruise and human-to-human transmission on board cannot be ruled out – although it is rare - the World Health Organization (WHO) said on Tuesday.
1
1
1
Edited News | OHCHR
UN rights chief concerned by upheld convictions of Cambodian activists.
1
1
1
Edited News | UNHCR , OHCHR
Middle East crisis puts aid, food, fuel further out of reach for millions already struggling – UN agencies
As the Middle East crisis continues the humanitarian fallout is worsening, with aid route disruptions and food and fuel price hikes wrecking the lives and rights of the most vulnerable, UN agencies warned on Friday.
1
1
2
Edited News | UNMAS
Demining experts from around the world have been sharing their collective shock at the widespread and growing threat from unexploded ordnance, the new head of the UN Mine Action Service (UNMAS) said on Wednesday.
1
1
1
Edited News | OHCHR , UNOG
The UN Human Rights Office in Syria conducted a 5-day visit to the northeast of the country where they received accounts of human rights violations and abuses.
1
1
1
Edited News | UNICEF
Sudan: ‘History repeating itself’ for Darfur’s children - UNICEF
Mass atrocities in Sudan’s Darfur 20 years ago reverberated as far as Hollywood, but today, a new generation of children faces attacks, hunger and displacement in an emergency largely ignored by the outside world, the UN Children’s Fund (UNICEF) warned on Tuesday.
1
1
Edited News | WHO , UNMAS
Desperate and dangerous conditions in Gaza continue to hamper recovery efforts for the wartorn enclave's people, the UN health agency said on Friday, while demining experts warned that they’ve “barely scratched the surface” in assessing the level of contamination of unexploded ordnance.